Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

REPROL53U48

Financiado

Cerrado

Characterization of direct reprogramming regulating factors LIN 53 and USP 48

"Cellular replacement therapies for treating degenerative diseases such as Alzheimer’s will require the generation of lost tissues by reprogramming cell types. While one strategy is to de-differentiate somatic cells into induced p... ver más

31/03/2017

MDC

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-03-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

MDC

0.00€ | Lider

Proyectos interesantes

CMR

Medical Technol...

Data Science

100K€ Cerrado

CellKarma

Medical Technol...

Data Science

1M€ Cerrado

CNS2023-144846

Medical Technol...

Data Science

200K€ Cerrado

PGC2018-098626-B-I00

Medical Technol...

Data Science

106K€ Cerrado

PLANMod

Medical Technol...

Data Science

1M€ Cerrado

BFU2012-33506

Medical Technol...

Data Science

234K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Cellular replacement therapies for treating degenerative diseases such as Alzheimer’s will require the generation of lost tissues by reprogramming cell types. While one strategy is to de-differentiate somatic cells into induced pluripotent stem cells with subsequent re-differentiation, an alternative strategy is to directly convert cells to the target cell type by using specific Transcription Factors (TFs). The latter strategy utilizes TFs that can induce specific cell fates; however, their ability to reprogram cell identities upon mis-expression is very limited. We are elucidating refractory mechanisms of direct cell fate conversion using C. elegans as a model organism. Using RNAi screens we recently identified LIN-53 (homolog of Rbbp4/7) as an inhibitor of reprogramming mitotic germ cells directly into specific neurons and muscle-like cells. At least six different chromatin regulatory complexes such as NURF/NuRD remodeling and histone modifying complexes share LIN-53. However, the molecular function of LIN-53 in different tissues and its exact role in regulating reprogramming remains elusive. Furthermore, forward genetics screens identified a ubiquitin specific protease (USP) to be involved in regulating direct reprogramming of hypodermal (skin) cells in worms. Nothing is known about this USP, only that its homolog is a direct target of the ectodermal master regulator p63 in human skin cells. Using 4D time-lapse imaging and tissue-specific biochemistry (ChIP-seq, SILAC) we aim to determine the spatio-temporal expression pattern of both factors in vivo and investigate their molecular function in controlling cell fate reprogramming. We will elucidate the regulatory network of these reprogramming factors by complementing our examinations with genetic analysis. Our findings might have broad implications for understanding mechanisms that restrict direct cell fate reprogramming and for generating specific tissues from different cellular contexts."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores